Literature DB >> 22476739

[Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

C Arsov1, D Blondin, R Rabenalt, G Antoch, P Albers, M Quentin.   

Abstract

BACKGROUND: The use of multi-parametric MRI and MRI-guided biopsy for the detection of prostate cancer is rapidly increasing. This is a pilot study to evaluate the consensus-based international MRI scoring system as decision criterion for targeted MRI-guided prostate biopsy.
MATERIAL AND METHODS: After a multi-parametric 3-T MRI (T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced MRI) in 23 consecutive patients a total of 47 lesions were scored according to a 5-point scale for each MRI sequence. A total score of ≥ 10 points was considered to be suspicious for prostate cancer. All 47 lesions were histologically assessed after MRI-guided biopsy.
RESULTS: At the cut-off score of 10 points, sensitivity, specificity, negative predictive value and positive predictive value of multi-parametric MRI were 94.1, 43.3, 92.9 and 48.5%, respectively.
CONCLUSIONS: A standardised scoring of lesions on multi-parametric MRI is feasible. The cut-off value leads to excellent values for sensitivity and negative predictive value. The values for specificity and positive predictive value are modest. Lesions with a total score <10 points are very unlikely to be malignant.

Entities:  

Mesh:

Year:  2012        PMID: 22476739     DOI: 10.1007/s00120-012-2825-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  20 in total

1.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.

Authors:  Aristotelis G Anastasiadis; Matthias P Lichy; Udo Nagele; Markus A Kuczyk; Axel S Merseburger; Joerg Hennenlotter; Stefan Corvin; Karl-Dietrich Sievert; Claus D Claussen; Arnulf Stenzl; Heinz-Peter Schlemmer
Journal:  Eur Urol       Date:  2006-03-24       Impact factor: 20.096

2.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Authors:  Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki Tsukuma
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

Review 3.  A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Authors:  Stijn W T P J Heijmink; Hilco van Moerkerk; Lambertus A L M Kiemeney; J Alfred Witjes; Ferdinand Frauscher; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

4.  Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.

Authors:  C S Stewart; B C Leibovich; A L Weaver; M M Lieber
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

5.  A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion.

Authors:  Boris A Hadaschik; Timur H Kuru; Corina Tulea; Philip Rieker; Ionel V Popeneciu; Tobias Simpfendörfer; Johannes Huber; Pawel Zogal; Dogu Teber; Sascha Pahernik; Matthias Roethke; Patrik Zamecnik; Wilfried Roth; Georgios Sakas; Heinz-Peter Schlemmer; Markus Hohenfellner
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

6.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

7.  Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.

Authors:  Tobias Franiel; Carsten Stephan; Andreas Erbersdobler; Ekkehart Dietz; Andreas Maxeiner; Nina Hell; Alexander Huppertz; Kurt Miller; Ralph Strecker; Bernd Hamm
Journal:  Radiology       Date:  2011-01-13       Impact factor: 11.105

8.  Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours.

Authors:  Leonardo Kayat Bittencourt; Jelle O Barentsz; Luiz Carlos Duarte de Miranda; Emerson Leandro Gasparetto
Journal:  Eur Radiol       Date:  2011-09-14       Impact factor: 5.315

9.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device.

Authors:  K Engelhard; H P Hollenbach; B Kiefer; A Winkel; K Goeb; D Engehausen
Journal:  Eur Radiol       Date:  2006-02-01       Impact factor: 5.315

10.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.

Authors:  Thomas Hambrock; Diederik M Somford; Caroline Hoeks; Stefan A W Bouwense; Henkjan Huisman; Derya Yakar; Inge M van Oort; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

View more
  3 in total

1.  Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy.

Authors:  Michael Quentin; Lars Schimmöller; Christian Arsov; Robert Rabenalt; Gerald Antoch; Peter Albers; Dirk Blondin
Journal:  Eur Radiol       Date:  2013-08-31       Impact factor: 5.315

2.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

3.  Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial.

Authors:  Christian Arsov; Robert Rabenalt; Michael Quentin; Andreas Hiester; Dirk Blondin; Peter Albers; Gerald Antoch; Lars Schimmöller
Journal:  World J Urol       Date:  2015-06-09       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.